Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H1 antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 10, 2009, Pages 2766-2771

  Kubota, Katsumi ^a   Kurebayashi, Hirotaka ^a   Miyachi, Hirotaka ^a   Tobe, Masanori ^a   Onishi, Masako ^a   Isobe, Yoshiaki ^a  

^a Dainippon Sumitomo Phrama Co Ltd   (Japan)

Author keywords

Antagonist; Carboxylic acid; H1; Histamine; Phenothiazine; Pyrimidine dione

Indexed keywords

AMINE; CARBOXYLIC ACID DERIVATIVE; HISTAMINE H1 RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; KETOTIFEN FUMARATE; OVALBUMIN; PHENOTHIAZINE DERIVATIVE; PREDNISOLONE; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; IN VIVO STUDY; MOUSE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CACO-2 CELLS; CARBOXYLIC ACIDS; CELL LINE, TUMOR; HISTAMINE H1 ANTAGONISTS; HUMANS; MICE; PHENOTHIAZINES; PYRIMIDINONES; RATS; RECEPTORS, HISTAMINE H1; STRUCTURE-ACTIVITY RELATIONSHIP;

MUS; RATTUS;

EID: 65349120142     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.03.124     Document Type: Article

References (27)

1. Holgate S.T., Canonica G.W., Simons F.E.R., Taglialatela M., Tharp M., Timmerman H., and Yanai K. Clin. Exp. Allg. 33 (2003) 1305
2. Morphy R., and Rankovic Z. J. Med. Chem. 48 (2005) 6523
3. Gyoten M., Nagaya H., Fukuda S., Ashida Y., and Kawano Y. Chem. Pharm. Bull. 51 (2003) 122
4. Fukuda S., Midoro K., Kamei T., Gyoten M., Kawano Y., Ashida Y., and Nagaya H. J. Pharmacol. Exp. Ther. 303 (2002) 1283
5. Fukuda S., Midoro K., Gyoten M., Kawano Y., Ashida Y., Nabe T., Kohno S., and Nagaya H. Eur. J. Pharm. 476 (2003) 239
6. Tobe M., Isobe Y., Goto Y., Obara F., Tsuchiya M., Matsui J., Hirota K., and Hayashi H. Bioorg. Med. Chem. 8 (2000) 2037
7. Isobe Y., Tobe M., Takahashi O., Goto Y., Inoue Y., Obara F., Tsuchiya M., and Hayashi H. Chem. Pharm. Bull. 50 (2002) 1418
8. Goto Y., Watanabe N., Kogawa N., Tsuchiya M., Takahashi O., Uchi H., Furue M., and Hayashi H. Eur. J. Pharmacol. 438 (2002) 189
9. Goto Y., Inoue Y., Tsuchiya M., Isobe M., Ueno T., Uchi H., Furue M., and Hayashi H. Int. Arch. Allg. Immunol. 123 (2000) 341
10. Isobe Y., Tobe M., Inoue Y., Tsuchiya M., and Hayashi H. Bioorg. Med. Chem. 11 (2003) 4933
11. Inoue Y., Isobe M., and Hayashi H. J. Pharmacol. Sci. 91 (2003) 71
12. Graul A., and Castaner J. Drugs Future 21 (1996) 1017
13. Markham A., and Wagstaff A.J. Drugs 55 (1998) 269
14. Simpson K., and Jarvis B. Drugs 59 (2000) 301
15. Kapsenberg M.L., Jansen H.M., Bos J.D., and Wierenga E.A. Curr. Opin. Immunol. 4 (1992) 788
16. Iwamoto I., Tomoe S., Tomioka H., Takatsu K., and Yoshida S. J. Leukocyte Biol. 52 (1992) 572
17. Sawada K., Nagai H., Basaki Y., Yamaya H., Ikizawa K., Watanabe M., Kojima M., Matsuura N., and Kiniwa M. Clin. Exp. Allg. 27 (1997) 225
18. Togawa M., Kiniwa M., and Nagai H. Life Sci. 69 (2001) 699
19. Uchi H., Koga T., Urabe K., Moroi Y., and Furue M. J. Invest. Dermatol. 120 (2003) 983
20. Tasaka K., Akagi M., Mio M., Izushi K., and Aoki I. Arzneim. Forsch. 40 (1990) 1092
21. Willgerodt C. Chem. Ber. 20 (1887) 2467
22. 3H]-pyrilamine in a total of 200 μl of binding buffer (50 mM Tris-HCl, pH 7.5). Nonspecific binding was determined in the presence of 1.25 μM triprolidine (Sigma). The assay mixture was incubated for 3 h at room temperature and then filtered through GF/B filters. These were washed and counted by a scintillation counter. Specific binding was calculated as the difference between total and nonspecific bindings.
23. 2), dC/dt: slope of the cumulative reserver concentration (μM/s).
24. Eight-week old female mice (ddY, SLC) was administered orally with various doses of compounds suspended in 0.5% methylcellulose 1 h before the intradermal injection of histamine (4 μg/site) to back skin following intravenous injections of Evans' blue solution. Thirty minutes after the injection of histamine, mice were sacrificed and the area of dye was measured.
25. Eight-week old female mice (Balb/c, SLC) were sensitized by intraperitoneal injection of OVA with alum. After two weeks, compounds suspended in a 0.5% MC solution was po administered 60 min before OVA injection to the ear in OVA-sensitized mice. Ear swellings were determined at 1 h (ITR) and 24 h (LTR) after elicitation. Each column with vertical bar represents the mean ± SE of 6-7 mice.
26. Oshima E., Otaki S., Sato H., Kumazawa T., Obase H., Ishii A., Ishii H., Ohmori K., and Hirayama N. J. Med. Chem. 35 (1992) 2074
27. 2O: C, 53.77; H, 6.18; N, 11.61; S, 5.31. Found: C, 53.38; H, 5.93; N, 11.34; S, 5.31.